Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trial.

de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L, CodeBreaK 200 Investigators.

Open source

DOI: 10.1016/s0140-6736(23)00221-0
Published: 2023-02-07
Container: Lancet
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-23-00221-0,
  title = {Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trial.},
  author = {de Langen AJ and  Johnson ML and  Mazieres J and  Dingemans AC and  Mountzios G and  Pless M and  Wolf J and  Schuler M and  Lena H and  Skoulidis F and  Yoneshima Y and  Kim SW and  Linardou H and  Novello S and  van der Wekken AJ and  Chen Y and  Peters S and  Felip E and  Solomon BJ and  Ramalingam SS and  Dooms C and  Lindsay CR and  Ferreira CG and  Blais N and  Obiozor CC and  Wang Y and  Mehta B and  Varrieur T and  Ngarmchamnanrith G and  Stollenwerk B and  Waterhouse D and  Paz-Ares L and  CodeBreaK 200 Investigators.},
  year = {2023},
  journal = {Lancet},
  doi = {10.1016/s0140-6736(23)00221-0},
  url = {https://doi.org/10.1016/s0140-6736(23)00221-0}
}

RIS

TY  - JOUR
TI  - Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trial.
AU  - de Langen AJ
AU  -  Johnson ML
AU  -  Mazieres J
AU  -  Dingemans AC
AU  -  Mountzios G
AU  -  Pless M
AU  -  Wolf J
AU  -  Schuler M
AU  -  Lena H
AU  -  Skoulidis F
AU  -  Yoneshima Y
AU  -  Kim SW
AU  -  Linardou H
AU  -  Novello S
AU  -  van der Wekken AJ
AU  -  Chen Y
AU  -  Peters S
AU  -  Felip E
AU  -  Solomon BJ
AU  -  Ramalingam SS
AU  -  Dooms C
AU  -  Lindsay CR
AU  -  Ferreira CG
AU  -  Blais N
AU  -  Obiozor CC
AU  -  Wang Y
AU  -  Mehta B
AU  -  Varrieur T
AU  -  Ngarmchamnanrith G
AU  -  Stollenwerk B
AU  -  Waterhouse D
AU  -  Paz-Ares L
AU  -  CodeBreaK 200 Investigators.
PY  - 2023
JO  - Lancet
DO  - 10.1016/s0140-6736(23)00221-0
UR  - https://doi.org/10.1016/s0140-6736(23)00221-0
ER  -

APA

AJ, D. L., ML, J., J, M., AC, D., G, M., M, P., J, W., M, S., H, L., F, S., Y, Y., SW, K., H, L., S, N., AJ, V. D. W., Y, C., S, P., E, F., BJ, S., SS, R., C, D., CR, L., CG, F., N, B., CC, O., Y, W., B, M., T, V., G, N., B, S., D, W., L, P., & Investigators., C. 2. (2023). Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trial.. Lancet. https://doi.org/10.1016/s0140-6736(23)00221-0

Source records

europe-pmc · retrieved 2026-09-26T05:24:59.399Z